Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

被引:321
|
作者
Eich, Hans Theodor
Diehl, Volker
Goergen, Helen
Pabst, Thomas
Markova, Jana
Debus, Juergen
Ho, Anthony
Doerken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Doehner, Hartmut
Borchmann, Peter
Mueller-Hermelink, Hans-Konrad
Mueller, Rolf-Peter
Engert, Andreas [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; INTERNATIONAL PROGNOSTIC SCORE; NODE RADIOTHERAPY; STAGE-I; DISEASE; CYCLES; PROGRESSION; RADIATION; SUPERIOR; THERAPY;
D O I
10.1200/JCO.2010.29.8018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. Conclusion Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
引用
收藏
页码:4199 / 4206
页数:8
相关论文
共 21 条
  • [1] Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
    von Tresckow, Bastian
    Pluetschow, Annette
    Fuchs, Michael
    Klimm, Beate
    Markova, Jana
    Lohri, Andreas
    Kral, Zdenek
    Greil, Richard
    Topp, Max S.
    Meissner, Julia
    Zijlstra, Josee M.
    Soekler, Martin
    Stein, Harald
    Eich, Hans T.
    Mueller, Rolf P.
    Diehl, Volker
    Borchmann, Peter
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 907 - 913
  • [2] ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials
    Boell, Boris
    Goergen, Helen
    Fuchs, Michael
    Pluetschow, Annette
    Eich, Hans Theodor
    Bargetzi, Mario J.
    Weidmann, Eckhart
    Junghanss, Christian
    Greil, Richard
    Scherpe, Alexander
    Schmalz, Oliver
    Eichenauer, Dennis A.
    von Tresckow, Bastian
    Rothe, Achim
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) : 1522 - 1529
  • [3] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352
  • [4] Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review Comparison of the results between two study generations of the German Hodgkin Study Group
    Kriz, J.
    Bangard, C.
    Haverkamp, U.
    Bongartz, R.
    Baues, C.
    Engert, A.
    Mueller, R-P
    Eich, H. T.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 660 - 665
  • [5] Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial
    Behringer, K.
    Thielen, I.
    Mueller, H.
    Goergen, H.
    Eibl, A. D.
    Rosenbrock, J.
    Halbsguth, T.
    Eichenauer, D. A.
    Fuchs, M.
    Reiners, K. S.
    Renno, J. H.
    van der Ven, K.
    Kuehr, M.
    von Wolff, M.
    Diehl, V.
    Engert, A.
    Borchmann, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1818 - 1825
  • [6] Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
    Sasse, Stephanie
    Broeckelmann, Paul J.
    Goergen, Helen
    Pluetschow, Annette
    Mueller, Horst
    Kreissl, Stefanie
    Buerkle, Carolin
    Borchmann, Sven
    Fuchs, Michael
    Borchmann, Peter
    Diehl, Volker
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18) : 1999 - +
  • [7] Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
    Advani, R. H.
    Hoppe, R. T.
    Baer, D.
    Mason, J.
    Warnke, R.
    Allen, J.
    Daadi, S.
    Rosenberg, S. A.
    Horning, S. J.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1044 - 1048
  • [8] Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy After Chemotherapy for Early-Stage Hodgkin's Lymphoma With Mediastinal Involvement
    Lu, Ning-Ning
    Li, Ye-Xiong
    Wu, Run-Ye
    Zhang, Xi-Mei
    Wang, Wei-Hu
    Jin, Jing
    Song, Yong-Wen
    Fang, Hui
    Ren, Hua
    Wang, Shu-Lian
    Liu, Yue-Ping
    Liu, Xin-Fan
    Chen, Bo
    Dai, Jian-Rong
    Yu, Zi-Hao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (01): : 210 - 216
  • [10] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
    Borchmann, Peter
    Haverkamp, Heinz
    Diehl, Volker
    Cerny, Thomas
    Markova, Jana
    Ho, Anthony D.
    Eich, Hans-Theodor
    Mueller-Hermelink, Hans Konrad
    Kanz, Lothar
    Greil, Richard
    Rank, Andreas
    Paulus, Ursula
    Smardova, Lenka
    Huber, Christoph
    Doerken, Bernd
    Nerl, Christoph
    Krause, Stefan W.
    Mueller, Rolf-Peter
    Fuchs, Michael
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242